Navigation Links
MediciNova Announces Positive Clinical Results From MN-166 Phase II,Multiple Sclerosis Trial

al MRI scans over 12 months of treatment was observed in patients treated with MN-166 compared to placebo, which was the protocol-defined primary endpoint of the study. No clinical or radiological benefit was observed in patients treated with 30 mg per day of MN-166. MN-166 was well tolerated at all doses in this trial. Eighty-nine percent of patients completed the first 12 months of the trial with only mild gastrointestinal side effects observed with MN-166 compared to placebo (3-6% vs. 1-3%, respectively).

The independent Data Safety Monitoring Board (DSMB) has recommended that the trial continue beyond the first year of treatment without modification and was supportive of further clinical evaluation of MN-166 in MS patients.

"We are pleased with the benefit of MN-166 observed in MS patients in this trial; they confirm the results of previous pilot trials of MN-166 in MS patients conducted by Japanese academic investigators," said Yuichi Iwaki, M.D., Ph.D., Executive Chairman and CEO of MediciNova, Inc. "The divergence of clinical benefit and radiological findings suggest that MN-166 may be acting by a different mode of action than current treatments. We will carefully analyze the clinical data with our independent advisors to determine next steps in the development program and to advance this compound into Phase III clinical testing."

In July 2005, MediciNova initiated a randomized, double-blind, placebo-controlled multi-center Phase II clinical trial of MN-166 in MS patients in five Eastern European countries. A total of 297 patients with at least one gadolinium-enhancing lesion on a screening visit MRI scan were randomized to receive placebo or one of two doses of MN-166 (30 or 60 mg per day) in this trial. Safety and efficacy assessments were performed at months 1, 2, 4, 6, 8, 10 and 12 of the trial. Efficacy assessments were based on the evaluation of the cumulative number of active (gadolinium-enhancing (T1) and non-enhancing new/enlargi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/17/2013)...  Sony Biotechnology Inc. ("Sony") today announced the launch of ... sorting chip.  Sony will also be exhibiting its newly rebranded ... Sorter, the EC800 flow cytometer, and new SP6800 Spectral Analyzer ... will be held at the San Diego ... , from May 20 - 22.  The ...
(Date:5/17/2013)... Research explores data on ... also   to   be presented ... the global specialty biopharmaceutical company, announces that it will ... American Psychiatric Association (APA) 166th Annual Meeting in ... being presented represent Shire,s ongoing commitment to the clinical ...
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- The escalation of new biological ... renewed emphasis on alternate delivery technologies. Alternate delivery ... of factors are converging to create both ... delivery device partners . These include new classes ... trend toward self-administration for chronic diseases, shifting patient ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3
... effectiveness for, patients, but Gilead Sciences and Merck and Co. ... ... LOS ANGELES, Sept. 10 AIDS Healthcare,Foundation (AHF) today called ... three-in-one, once daily lifesaving HIV,treatment, Atripla, in developing countries. When ...
... BioMosaics Inc., a cancer,biomarker development company, announced today ... products for the identification of Glypican-3,(GPC3) in human ... tests. This will,allow the GPC3 (Human Glypican-3) ELISA ... and the GPC3 (Human Glypican-3) Monoclonal Antibody (clone,1G12) ...
Cached Medicine Technology:Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations 2Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations 3BioMosaics' Glypican-3 Blood & Tissue Tests Receive CE Marking in Europe 2
(Date:5/19/2013)... Americans live closer to their dogs ... Veterinary Medical Association (AVMA) U.S. Pet Ownership and Demographics ... their dog a member of the family, up from ... five years earlier. , According to the American Pet ... income dedicated to pets has increased every year without ...
(Date:5/19/2013)... The Fat Loss Code program developed by Shawn Stevenson covers ... get in shape, and gain a healthy life regardless of ... a natural fat loss system that provides people with effective ... loss diet program claimed that The Fat Loss Code is ... fat off long-term. After Shawn Stevenson launched this new body ...
(Date:5/19/2013)... Wa (PRWEB) May 19, 2013 Agora Health ... program that covers guides on how to increase memory ... innovative memory training method that helps people re-new their entire ... stress and beat depression caused by a fatigued mind. In ... mind razor sharp for a lifetime. The author claimed that ...
(Date:5/19/2013)... 2013 Beginning Wednesday, May 29 and running ... (RRVBC) will feature “Hot Dog Wednesdays" and Ice Cold Slushies ... provide hot dogs and all the fixin's to donors on ... throughout the summer. “Donors are our lifeline. The summer months ... adequate blood supply. This is a small way for ...
(Date:5/19/2013)... HealthEconomics.Com , the global leader ... unveil a new and exciting service: HE-Xpo: a media-rich, ... array of real-time communication tools to expand their digital ... , HE-Xpo is powered by OnStream Media’s ... feel of being at a physical trade show, all ...
Breaking Medicine News(10 mins):Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3Health News:Weight Loss Secrets | How “The Fat Loss Code” Helps People Gain A Healthy Life And Get In Shape - Health Review 2Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3
... FRANCISCO, Dec. 16 Medizone International, Inc. (OTC Bulletin Board: ... the Board of Medizone New Zealand Ltd., a joint venture ... on December 14, 2009 to unwind the joint venture and ... company,s intellectual property. Medizone International,s Chairman, Edwin G. Marshall ...
... Americans have myopia now than in the ,70s, study finds ... more common in the United States than it was more ... , Researchers compared National Health and Nutrition Examination Survey data ... and from 8,339 black and white participants from 1999 to ...
... triathalons and appeared on The Amazing Race , ... think of herself as part human, part machine. , A ... triathlete likes to describe herself. When she,s not training for ... auditoriums or posing nude with her metal leg crossed over ...
... ... in capital funding to scale up production and support of the EmbryoScope™ Embryo Monitoring ... capital was invested by LD Pensions and Unisense A/S that continue to own each about ... ...
... ... Podiatric Medical Association’s Seal of Acceptance , ... Bethesda, MD (Vocus) December 15, 2009 -- As shoppers continue ... and shop for items that are considered healthy for the environment. When it comes ...
... ... development of products that help survivors of stroke and other forms of traumatic brain injury ... new device for stroke rehabilitation, the Tailwind. (Advance for Physical Therapy and Rehab Medicine, vol. ... ...
Cached Medicine News:Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:Amputee Athlete Tells Her Story 2Health News:Amputee Athlete Tells Her Story 3Health News:Amputee Athlete Tells Her Story 4Health News:Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 2Health News:Put Some "Green" Into Gift-Giving With Eco-Friendly Footwear Products 2Health News:Put Some "Green" Into Gift-Giving With Eco-Friendly Footwear Products 3Health News:Put Some "Green" Into Gift-Giving With Eco-Friendly Footwear Products 4Health News:New Tailwind Device Improves Arm Function in Stroke Survivors with Paralysis 2
The VISERA Multi-Specialty Digital Imaging Platform is the world's first integrated system of digital rigid, deflectable tip and flexible videoscopes for use in operating room endosurgery as well as ...
... of oxygen and carbon dioxide, originally developed ... a number of different applications, including vascular ... and orthopedic surgery. TcpO2 measurements usually require ... provide a good picture. The more sites ...
For continuous intracranial monitoring of pressure, oxygen and temperature of the brain...
Cutting Burr with dental shank, tungsten carbide, 0,7 mm, ISO-No. 007, packing unit 10 pieces....
Medicine Products: